Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2014
04/01/2014US8685422 High alcohol content foaming compositions with silicone-based surfactants
04/01/2014US8685397 Combination therapy for the treatment of ocular neovascular disorders
04/01/2014US8685383 Protein-polymer-drug conjugates
04/01/2014US8685382 Temperature sensitive polymers
04/01/2014US8685381 Topical base and active agent-containing compositions, and methods for improving and treating skin
04/01/2014US8685374 EDTA containing compositions and uses thereof
04/01/2014CA2770766C Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
04/01/2014CA2769490C Improved pharmacokinetics of s-adenosylmethionine formulations
04/01/2014CA2749212C Isoxazole / o-pyridine derivatives with ethyl and ethenyl linker
04/01/2014CA2729212C Compounds and methods for modulating g protein-coupled receptors
04/01/2014CA2696630C Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
04/01/2014CA2692606C Inhalable solid amorphous particles comprising tiotropiium bromide and a co-solid
04/01/2014CA2681668C Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
04/01/2014CA2669767C Progesterone receptor antagonists
04/01/2014CA2655789C Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
04/01/2014CA2654515C Substituted 3-cyanopyridines as protein kinase inhibitors
04/01/2014CA2654318C Sulphimides as protein kinase inhibitors
04/01/2014CA2652712C Stabilized pharmaceutical compositions comprising fesoterodine
04/01/2014CA2648019C Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
04/01/2014CA2645946C Inhibitors of protein aggregation
04/01/2014CA2637302C Vitamin d analog-rak, methods and uses thereof
04/01/2014CA2636436C Long term treatment of hiv- infection with tmc278
04/01/2014CA2633958C Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
04/01/2014CA2631872C Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
04/01/2014CA2628952C Aspartic protease inhibitors
04/01/2014CA2624372C Microparticles with modified release of at least one active principle and oral galenic form comprising same
04/01/2014CA2620469C Methods of modulating intestinal fluid balance
04/01/2014CA2619919C Diaminopyrimidines as p2x3 and p2x2/3 modulators
04/01/2014CA2616377C Nitrocatechol derivatives as comt inhibitors
04/01/2014CA2594098C Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
04/01/2014CA2589521C Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
04/01/2014CA2581144C Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
04/01/2014CA2569590C Drug having regulatory cell ligand contained in liposome
04/01/2014CA2567404C Cyclopenta[b]benzofuran derivatives and the utilization thereof
04/01/2014CA2556086C Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
04/01/2014CA2506238C Chroman derived compounds & formulations thereof for use in therapy
04/01/2014CA2498523C Human cd3-specific antibody with immunosuppressive properties
04/01/2014CA2493928C Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
04/01/2014CA2488677C Method of inhibiting prostate cancer cell proliferation
04/01/2014CA2486483C Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
04/01/2014CA2405377C Nutritional modules
03/2014
03/27/2014WO2014047648A1 Certain chemical entities, compositions, and methods
03/27/2014WO2014047614A1 Nutritional compositions and methods for enhancing cognitive function and muscle function
03/27/2014WO2014047592A2 Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
03/27/2014WO2014047588A1 Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
03/27/2014WO2014047569A2 Product comprising a nicotine-containing material and an anti-cancer agent
03/27/2014WO2014047562A2 Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain
03/27/2014WO2014047551A1 Flavonoid based antiviral targets
03/27/2014WO2014047519A2 Inhibitors of beta-hydrolase for treatment of cancer
03/27/2014WO2014047506A1 Methods for treatment or prevention of damage resulting from radiation, trauma or shock
03/27/2014WO2014047497A1 Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
03/27/2014WO2014047493A1 Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein
03/27/2014WO2014047476A1 Compositions and methods for improving health in animals
03/27/2014WO2014047447A2 Fto modulating compounds and methods of use
03/27/2014WO2014047437A1 3-3-di-substituted-oxindoles as inhibitors of translation initiation
03/27/2014WO2014047413A1 Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
03/27/2014WO2014047398A1 Modulation of asymmetric proliferation
03/27/2014WO2014047397A1 Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
03/27/2014WO2014047393A1 N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
03/27/2014WO2014047392A1 Fluoroalkyl-1,4-benzodiazepinone compounds
03/27/2014WO2014047391A1 Prodrugs of 1,4-benzodiazepinone compounds
03/27/2014WO2014047390A1 Tricyclic heterocyclic compounds as notch inhibitors
03/27/2014WO2014047372A1 Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
03/27/2014WO2014047369A1 Substituted 1,5-benzodiazepinone compounds
03/27/2014WO2014047362A1 Compositions and methods for improving or preventing depression-like symptoms
03/27/2014WO2014047330A1 Novel raf kinase inhibitors
03/27/2014WO2014047328A2 Pkc delta inhibitors for use as therapeutics
03/27/2014WO2014047325A1 Sgc stimulators
03/27/2014WO2014047323A1 Methods for treating post-traumatic stress disorder
03/27/2014WO2014047321A1 Compositions and methods for increasing human growth hormone levels
03/27/2014WO2014047320A1 Methods for improving linear growth response in children
03/27/2014WO2014047314A1 Methods for improving thyroid function in healthy humans
03/27/2014WO2014047305A1 Methods and compositions for increasing growth hormones
03/27/2014WO2014047285A1 Identifying taxane sensitivity in prostate cancer patients
03/27/2014WO2014047257A2 Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
03/27/2014WO2014047251A1 Methods of treating pulmonary fibrosis
03/27/2014WO2014047221A1 Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium
03/27/2014WO2014047212A1 Compositions and methods comprising oxadiazole derivatives
03/27/2014WO2014047167A1 Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
03/27/2014WO2014047111A1 Sgc stimulators
03/27/2014WO2014047109A1 Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor
03/27/2014WO2014047048A1 Methods for treating hepatitis c
03/27/2014WO2014047046A1 Methods for treating hepatitis c
03/27/2014WO2014047039A1 Methods for treating hepatitis c
03/27/2014WO2014047024A1 Iap antagonists
03/27/2014WO2014047021A1 Cinnamaldehyde and diallyl disulfide formulations and methods of use
03/27/2014WO2014047020A1 Dihydropyrrolidino-pyrimidines as kinase inhibitors
03/27/2014WO2014047007A1 Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
03/27/2014WO2014047005A1 Sustained release oral dosage forms comprising low melting propionic acid derivative particles
03/27/2014WO2014046983A1 Method of treating cancer
03/27/2014WO2014046753A2 Method and system for treatment of biological tissue
03/27/2014WO2014046744A1 Method and system for treatment of biological tissue
03/27/2014WO2014046722A1 Treatment compositions
03/27/2014WO2014046671A1 No-releasing polymers and uses thereof
03/27/2014WO2014046636A1 Antibacterial agent
03/27/2014WO2014046617A1 Compositions and methods for treating cancer
03/27/2014WO2014046603A1 Compositions for improvement of brain function
03/27/2014WO2014046589A1 Means and method for treating solid tumours
03/27/2014WO2014046544A1 Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
03/27/2014WO2014046474A2 Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease
1 ... 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 ... 7860